{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T16:54:18Z","timestamp":1687625658658},"reference-count":43,"publisher":"Georg Thieme Verlag KG","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1055\/a-1303-8820","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:18:00Z","timestamp":1630023480000},"page":"1108-1118","source":"Crossref","is-referenced-by-count":1,"title":["Checkpoint-Inhibitoren \u2013 aktuelle Versorgungsstandards und Zukunftstrends"],"prefix":"10.1055","volume":"146","author":[{"given":"Anna","family":"Reischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"T F Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"D M Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/jco.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"D Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"J J Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/14737140.2019.1699407","article-title":"Durvalumab for the treatment of non-small cell lung cancer","volume":"19","author":"S Murakami","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.7888\/juoeh.40.173","article-title":"Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC)","volume":"40","author":"K Yoneda","year":"2018","journal-title":"J uoeh"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The Effect of Advances in Lung-Cancer Treatment on Population Mortality","volume":"383","author":"N Howlader","year":"2020","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cancers13010131","article-title":"Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer","volume":"13","author":"A Lopez-Beltran","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/10732748211004878","article-title":"Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker","volume":"28","author":"K Oualla","year":"2021","journal-title":"Cancer Control"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/s1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"K Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"T Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/cancers11081071","article-title":"Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies","volume":"11","author":"T P Vassilakopoulos","year":"2019","journal-title":"Cancers (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"7229","DOI":"10.2147\/ott.S255491","article-title":"Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer","volume":"13","author":"W Liu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"P Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"S1147","DOI":"10.1016\/j.annonc.2020.08.2243","article-title":"LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) \u00b1 atezolizumab (atezo) for unresectable locally advanced\/metastatic triple-negative breast cancer (mTNBC)","volume":"31","author":"D W Miles","year":"2020","journal-title":"Annals of Oncology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"GS3-01","DOI":"10.1158\/1538-7445.Sabcs20-gs3-01","article-title":"Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer","volume":"81","author":"H S Rugo","year":"2021","journal-title":"Cancer Research"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1007\/s00103-020-03221-9","article-title":"[Checkpoint inhibitors for cancer therapy]","volume":"63","author":"H Zander","year":"2020","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/s1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"L Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"D Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer","volume":"377","author":"S J Antonia","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","author":"S J Antonia","year":"2018","journal-title":"The New England journal of medicine"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/s1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"N Y Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"eabg0117","DOI":"10.1126\/sciimmunol.abg0117","article-title":"Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses","volume":"6","author":"J Wei","year":"2021","journal-title":"Sci Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40425-018-0393-z","article-title":"Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases","volume":"6","author":"C A Garcia","year":"2018","journal-title":"Journal for immunotherapy of cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"J Weber","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer","volume":"384","author":"R J Kelly","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","author":"C U Blank","year":"2018","journal-title":"Nature medicine"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"P M Forde","year":"2018","journal-title":"New England Journal of\u00a0Medicine"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"M Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41379-020-0644-7","article-title":"Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)","volume":"34","author":"E J de Ruiter","year":"2020","journal-title":"Mod Pathol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"610","DOI":"10.21037\/jgo.2018.05.06","article-title":"Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition","volume":"9","author":"D A Fabrizio","year":"2018","journal-title":"Journal of Gastrointestinal Oncology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2020.38.15_suppl.3008","article-title":"Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy","volume":"38","author":"B Garmezy","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e1310358","DOI":"10.1080\/2162402x.2017.1310358","article-title":"Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer","volume":"6","author":"S Kruger","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"S V Bratman","year":"2020","journal-title":"Nature Cancer"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/2159-8290.Cd-20-0047","article-title":"Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade","volume":"10","author":"Q Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/s0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"A Sezer","year":"2021","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC","volume":"383","author":"R S Herbst","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"T Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/s1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"A J Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2217\/fon-2018-0609","article-title":"KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer","volume":"15","author":"K Kato","year":"2019","journal-title":"Future Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1016\/j.annonc.2021.05.051","article-title":"SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"32","author":"T Andr\u00e9","year":"2021","journal-title":"Annals of Oncology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/s0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"P Baas","year":"2021","journal-title":"Lancet"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"T K Choueiri","year":"2021","journal-title":"N Engl J Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1303-8820.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:18:23Z","timestamp":1630023503000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1303-8820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":43,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,8,26]]},"published-print":{"date-parts":[[2021,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1303-8820","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]}}}